Literature DB >> 19637187

Abnormal hepatic energy homeostasis in type 2 diabetes.

Julia Szendroedi1, Marek Chmelik, Albrecht Ingo Schmid, Peter Nowotny, Attila Brehm, Martin Krssak, Ewald Moser, Michael Roden.   

Abstract

UNLABELLED: Increased hepatocellular lipids relate to insulin resistance and are typical for individuals with type 2 diabetes mellitus (T2DM). Steatosis and T2DM have been further associated with impaired muscular adenosine triphosphate (ATP) turnover indicating reduced mitochondrial fitness. Thus, we tested the hypothesis that hepatic energy metabolism could be impaired even in metabolically well-controlled T2DM. We measured hepatic lipid volume fraction (HLVF) and absolute concentrations of gammaATP, inorganic phosphate (Pi), phosphomonoesters and phosphodiesters using noninvasive (1)H/ (31)P magnetic resonance spectroscopy in individuals with T2DM (58 +/- 6 years, 27 +/- 3 kg/m (2)), and age-matched and body mass index-matched (mCON; 61 +/- 4 years, 26 +/- 4 kg/m (2)) and young lean humans (yCON; 25 +/- 3 years, 22 +/- 2 kg/m (2), P < 0.005, P < 0.05 versus T2DM and mCON). Insulin-mediated whole-body glucose disposal (M) and endogenous glucose production (iEGP) were assessed during euglycemic-hyperinsulinemic clamps. Individuals with T2DM had 26% and 23% lower gammaATP (1.68 +/- 0.11; 2.26 +/- 0.20; 2.20 +/- 0.09 mmol/L; P < 0.05) than mCON and yCON individuals, respectively. Further, they had 28% and 31% lower Pi than did individuals from the mCON and yCON groups (0.96 +/- 0.06; 1.33 +/- 0.13; 1.41 +/- 0.07 mmol/L; P < 0.05). Phosphomonoesters, phosphodiesters, and liver aminotransferases did not differ between groups. HLVF was not different between those from the T2DM and mCON groups, but higher (P = 0.002) than in those from the yCON group. T2DM had 13-fold higher iEGP than mCON (P < 0.05). Even after adjustment for HLVF, hepatic ATP and Pi related negatively to hepatic insulin sensitivity (iEGP) (r =-0.665, P = 0.010, r =-0.680, P = 0.007) but not to whole-body insulin sensitivity.
CONCLUSION: These data suggest that impaired hepatic energy metabolism and insulin resistance could precede the development of steatosis in individuals with T2DM.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19637187     DOI: 10.1002/hep.23093

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  72 in total

1.  p110α Hot Spot Mutations E545K and H1047R Exert Metabolic Reprogramming Independently of p110α Kinase Activity.

Authors:  Aditi Chaudhari; Daniel Krumlinde; Annika Lundqvist; Levent M Akyürek; Sashidhar Bandaru; Kristina Skålén; Marcus Ståhlman; Jan Borén; Yvonne Wettergren; Katarina Ejeskär; Victoria Rotter Sopasakis
Journal:  Mol Cell Biol       Date:  2015-07-13       Impact factor: 4.272

2.  Challenging dogma: is hepatic lipid accumulation in type 2 diabetes due to mitochondrial dysfunction?

Authors:  Christopher G R Perry; David C Wright
Journal:  J Physiol       Date:  2016-08-01       Impact factor: 5.182

3.  Monitoring acute metabolic changes in the liver and kidneys induced by fructose and glucose using hyperpolarized [2-13 C]dihydroxyacetone.

Authors:  Irene Marco-Rius; Cornelius von Morze; Renuka Sriram; Peng Cao; Gene-Yuan Chang; Eugene Milshteyn; Robert A Bok; Michael A Ohliger; David Pearce; John Kurhanewicz; Peder E Z Larson; Daniel B Vigneron; Matthew Merritt
Journal:  Magn Reson Med       Date:  2016-11-17       Impact factor: 4.668

Review 4.  The role of mitochondria in insulin resistance and type 2 diabetes mellitus.

Authors:  Julia Szendroedi; Esther Phielix; Michael Roden
Journal:  Nat Rev Endocrinol       Date:  2011-09-13       Impact factor: 43.330

Review 5.  Intracellular lipid accumulation and shift during diabetes progression.

Authors:  Peter Wolf; Yvonne Winhofer; Christian-Heinz Anderwald; Martin Krššák; Michael Krebs
Journal:  Wien Med Wochenschr       Date:  2014-07-22

Review 6.  Nonalcoholic fatty liver disease: current issues and novel treatment approaches.

Authors:  Romina Lomonaco; Nishanth E Sunny; Fernando Bril; Kenneth Cusi
Journal:  Drugs       Date:  2013-01       Impact factor: 9.546

Review 7.  The hepatic cannabinoid 1 receptor as a modulator of hepatic energy state and food intake.

Authors:  Martin E Cooper; Simon E Regnell
Journal:  Br J Clin Pharmacol       Date:  2014-01       Impact factor: 4.335

8.  Hungry for your alanine: when liver depends on muscle proteolysis.

Authors:  Theresia Sarabhai; Michael Roden
Journal:  J Clin Invest       Date:  2019-11-01       Impact factor: 14.808

9.  Fructose tolerance test in obese people with and without type 2 diabetes.

Authors:  Ebaa Al-Ozairi; Christopher J Rivard; Laura Gabriela Sanchez Lozada; Miguel A Lanaspa; Petter Bjornstad; Danah Al Salem; Asma Alhubail; Amira Megahed; Masanari Kuwabara; Richard J Johnson; Reem A Asad
Journal:  J Diabetes       Date:  2019-09-18       Impact factor: 4.006

10.  Hepatic mitochondrial oxidative phosphorylation is normal in obese patients with and without type 2 diabetes.

Authors:  Michael Taulo Lund; Marianne Kristensen; Merethe Hansen; Louise Tveskov; Andrea Karen Floyd; Mikael Støckel; Ben Vainer; Steen Seier Poulsen; Jørn Wulff Helge; Clara Prats; Flemming Dela
Journal:  J Physiol       Date:  2016-08-01       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.